Compare SYF & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SYF | RPRX |
|---|---|---|
| Founded | 1932 | 1996 |
| Country | United States | United States |
| Employees | 20000 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.0B | 19.7B |
| IPO Year | N/A | 2020 |
| Metric | SYF | RPRX |
|---|---|---|
| Price | $66.96 | $45.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 4 |
| Target Price | ★ $86.42 | $47.75 |
| AVG Volume (30 Days) | ★ 3.7M | 2.9M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | 1.81% | ★ 2.07% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.78 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | $86.60 | $38.30 |
| Revenue Next Year | $4.95 | $4.80 |
| P/E Ratio | ★ $7.85 | $25.45 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $40.55 | $29.66 |
| 52 Week High | $88.77 | $47.86 |
| Indicator | SYF | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.67 | 54.42 |
| Support Level | $63.08 | $44.94 |
| Resistance Level | $75.21 | $46.14 |
| Average True Range (ATR) | 1.69 | 0.82 |
| MACD | 0.32 | -0.24 |
| Stochastic Oscillator | 56.95 | 32.43 |
Synchrony Financial, originally a spinoff of GE Capital's retail financing business, is the largest provider of private-label credit cards in the United States by both outstanding receivables and purchasing volume. Synchrony partners with other firms to market its credit products in their physical stores as well as on their websites and mobile applications. Synchrony operates through three segments: retail card (private-label and co-branded general-purpose credit cards), payment solutions (promotional financing for large ticket purchases), and CareCredit (financing for elective healthcare procedures).
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.